>
Switch to:

Allergy Therapeutics Equity-to-Asset

: 0.55 (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Allergy Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2021 was $68.1 Mil. Allergy Therapeutics's Total Assets for the quarter that ended in Jun. 2021 was $123.5 Mil. Therefore, Allergy Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2021 was 0.55.

The historical rank and industry rank for Allergy Therapeutics's Equity-to-Asset or its related term are showing as below:

OTCPK:AGYTF' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.05   Med: 0.52   Max: 0.86
Current: 0.55

-1.05
0.86

During the past 13 years, the highest Equity to Asset Ratio of Allergy Therapeutics was 0.86. The lowest was -1.05. And the median was 0.52.

OTCPK:AGYTF's Equity-to-Asset is ranked higher than
55% of the 154 Companies
in the Drug Manufacturers industry.

( Industry Median: 0.58 vs. OTCPK:AGYTF: 0.55 )

Allergy Therapeutics Equity-to-Asset Historical Data

The historical data trend for Allergy Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.45 0.55 0.51 0.55

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.58 0.51 0.59 0.55

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics Equity-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Equity-to-Asset falls into.



Allergy Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Allergy Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2021 is calculated as

Equity to Asset (A: Jun. 2021 )=Total Stockholders Equity/Total Assets
=68.071528751753/123.54698457223
=0.55

Allergy Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2021 is calculated as

Equity to Asset (Q: Jun. 2021 )=Total Stockholders Equity/Total Assets
=68.071528751753/123.54698457223
=0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Allergy Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)